HIKAL · NSE
Hikal Limited
₹226.04
+0.33% (+₹0.75)
Prev. close
₹225.29
Volume
3,82,596
Delivery %
38.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Jai Vishwanath Hiremath
Headquarters
Navi Mumbai
Employees
2,152
Website
hikal.comExchange
View on NSE ↗Key stats
Market cap
₹2,787.09 Cr
Dividend yield
0.27%
EPS (TTM)
₹-2.75
Beta (1Y · daily vs NIFTY 50)
1.58
Beta (5Y · monthly vs NIFTY 50)
1.65
Shares float
3.81 Cr
EPS · quarter ended Jun 2026
₹-0.60
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.9% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,720.44 Cr | ₹1,942.72 Cr | ₹2,023.03 Cr | ₹1,784.60 Cr | ₹1,859.80 Cr | ₹1,712.60 Cr | |
| EBITDA | ₹327.87 Cr | ₹345.45 Cr | ₹262.48 Cr | ₹269.48 Cr | ₹333.40 Cr | ₹147.60 Cr |
| ₹133.15 Cr | ₹160.00 Cr | ₹78.38 Cr | ₹69.60 Cr | ₹90.80 Cr | ₹-48.80 Cr | |
| Diluted EPS | ₹10.8 | ₹13.02 | ₹6.36 | ₹5.64 | ₹7.36 | ₹-3.96 |
Total expenses (as filed), Employee benefit expense, Other expenses, Tax provision, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,913.00 Cr | ₹2,213.00 Cr | ₹2,385.00 Cr | ₹2,487.00 Cr | ₹2,529.00 Cr | ₹2,365.00 Cr | |
| ₹610.25 Cr | ₹675.02 Cr | ₹748.18 Cr | ₹817.60 Cr | ₹764.70 Cr | ₹683.80 Cr | |
| Stockholders' equity | ₹934.00 Cr | ₹1,068.00 Cr | ₹1,134.00 Cr | ₹1,188.00 Cr | ₹1,263.00 Cr | ₹1,199.00 Cr |
Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹229.00 Cr | ₹294.00 Cr | ₹315.00 Cr | ₹187.00 Cr | ₹280.00 Cr | ₹302.00 Cr | |
| Investing cash flow | ₹-156.19 Cr | — | ₹-292.33 Cr | ₹-173.75 Cr | ₹-136.50 Cr | ₹-145.30 Cr |
| ₹-96.87 Cr | — | ₹-7.69 Cr | ₹-27.00 Cr | ₹-143.60 Cr | ₹-160.10 Cr | |
| Capital expenditure | ₹-158.00 Cr | ₹-273.00 Cr | ₹-303.00 Cr | ₹-204.00 Cr | ₹-137.00 Cr | ₹-148.00 Cr |
| End cash position | ₹7.64 Cr | ₹11.44 Cr | ₹26.73 Cr | ₹12.70 Cr | ₹13.00 Cr | ₹9.60 Cr |
Investing cash flow, Financing cash flow have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 21–Sep 22(6Q) | Dec 22 | Mar 23–Jun 26(14Q) |
|---|---|---|---|
| Promoter | 68.77% | 68.83% | 68.85% |
| Public | 31.23% | 31.17% | 31.15% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Hikal Limited | ₹2,777.84 Cr | ₹226.04 | — | 2.32 | -4.1% | 0.57 | -8.0% | -15.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Don't Race Out To Buy Hikal Limited (NSE:HIKAL) Just Because It's Going Ex-Dividend
Hikal Limited is approaching its ex-dividend date, with investors purchasing shares on or after September 4 not receiving the upcoming ₹0.40 per share dividend. The company paid a dividend last year despite being unprofitable, though it was covered by free cash flow. Hikal's earnings have declined over the past five years, and its dividend has decreased by 1.0% annually over the last decade.